Adaptive Biotechnologies Corporation ADPT
29.94 USD +0.58 (+1.98%)
At closeNov 11, 2026, 6:13 PM EST
29.55 -0.39 -1.30%
After hours · Nov 11, 6:13 PM ET
29.83 Day range 32.13
12.00 52-week range 32.13
- YTD
- +84.36%
- 1 year
- +106.06%
News
globenewswire.com Adaptive Biotechnologies to Participate in Upcoming Investor Conferences SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the…
zacks.com Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $32 to $34.
defenseworld.net Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Has Average Target Price of $30.06 Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm,…
seekingalpha.com Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
zacks.com Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates Adaptive Biotechnologies (ADPT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.15 per share a…
zacks.com Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics…
marketbeat.com Adaptive Biotechnologies Q3 Earnings Call Highlights Adaptive Biotechnologies NASDAQ: ADPT reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing…
benzinga.com Adaptive Biotechnologies Q3 2026 Earnings Call Transcript Adaptive Biotechnologies (NASDAQ:ADPT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the…
seekingalpha.com Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure Adaptive Biotechnologies benefits from new NCCN guidelines and IMS cure definitions, positioning clonoSEQ as the standard for long-term myeloma MRD monitoring. MRD revenues grew 33% year-over-year to…
defenseworld.net Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Company Stock Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the business's stock in a transaction on Friday, October 23rd. The shares were sold at…
defenseworld.net Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Stock Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the firm's stock in a transaction on Monday, October 26th. The stock was sold at an…
benzinga.com MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session Brazilian stocks plunged premarket after Lula's reelection, led by XP (-46%), Inter & Co (-34.7%), StoneCo (-33.8%) and MercadoLibre (-14.1%).
seekingalpha.com Alger Small Cap Focus Fund Q3 2026 Portfolio Update Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and…
defenseworld.net Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $304,272.41 in Stock Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were…
globenewswire.com Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026 SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune…
benzinga.com TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32 TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.- benzinga.com Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27 Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.
gurufocus.com Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100 On October 12, 2026, Adaptive Biotechnologies Corp (ADPT) shares fell 3.5%, currently trading at $25.57. The stock has seen significant volatility, with a 52-we
defenseworld.net Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Rated “Moderate Buy” by Sell-Side Brokerages Shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm,…
defenseworld.net Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Still a Buy? Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $30.10 and last traded at $30.3490, with…
benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $32.- benzinga.com Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35 Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.
globenewswire.com Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune…
defenseworld.net Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT) Adaptive Biotechnologies (NASDAQ: ADPT - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior business?…
benzinga.com BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34 BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $34.
defenseworld.net Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High – Should You Buy? Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) shares hit a new 52-week high during trading on Tuesday. The company traded as high as $28.78 and last traded at $27.86, with a…
benzinga.com Adaptive Biotechnologies Highlights NCCN Guideline Updates Naming clonoSEQ For MRD Assessment In Multiple Myeloma Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journeyclonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6…
benzinga.com ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
benzinga.com Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5 Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.- benzinga.com Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22 Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.
benzinga.com TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28 TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.- benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $22 to $25.
- benzinga.com BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25 BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.
- benzinga.com UPDATE: Adaptive Biotechnologies Q2 Adj. EPS $(0.10) Beats $(0.13) Estimate, Sales $71.553M Beat $65.886M Estimate Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 41.18 percent increase over…
benzinga.com Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.14) by 78.57 percent. This is a 47.06 percent decrease over…- benzinga.com Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20 Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $18 to $20.
- benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $21 to $22.
benzinga.com KB Home Posts Upbeat Q2 Sales, Joins Inmode, Icon And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares jumped 16.2%. Other big gainers: WEN, ABSI, RUN, CCXI, ENRD, SFTX, ICCM, INMD, DFH.
benzinga.com Adaptive Biotechnologies Business Separation May Unlock Greater Value William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve flexibility and support valuation.- benzinga.com BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.
- benzinga.com Adaptive Biotechnologies Prices $300M Upsized Convertible Notes Offering (Up From $250M) Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes…
benzinga.com Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses Adaptive Biotechnologies plans to separate its businesses as clonoSEQ profitability and revenue growth accelerate.
benzinga.com Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED) (Editor’s note: The lede, headline, futures and economic data were updated.) U.S. stock futures were mixed on Tuesday, as the Dow Jones rose, while the Nasdaq 100 and S&P 500 declined, following…
benzinga.com Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market trading
benzinga.com Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open. Other gainers include SLBT, TDIC, IMCC, IVDA, NXTS, CRVO, PAVS, ALBT, and PURR. Losers include…
benzinga.com John Wiley & Sons, Dave and Buster's Entertainment And 3 Stocks To Watch Heading Into Tuesday Stock futures lower, Wiley & Sons and Vince Holding expected to report earnings, Dave & Buster's and Adaptive Biotechnologies saw after-hours trading dips.
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Earnings Scheduled For February 5, 2026